BR9815580A - Composição de vacina, processos para gerar uma resposta de anti-idiótipo em um sujeito, para tratar ou prevenir câncer, para tratar ou prevenir uma doença infecciosa, para preparar uma primeira molécula de imunoglobulina, e, primeira molécula de imunoglobulina - Google Patents

Composição de vacina, processos para gerar uma resposta de anti-idiótipo em um sujeito, para tratar ou prevenir câncer, para tratar ou prevenir uma doença infecciosa, para preparar uma primeira molécula de imunoglobulina, e, primeira molécula de imunoglobulina

Info

Publication number
BR9815580A
BR9815580A BR9815580-6A BR9815580A BR9815580A BR 9815580 A BR9815580 A BR 9815580A BR 9815580 A BR9815580 A BR 9815580A BR 9815580 A BR9815580 A BR 9815580A
Authority
BR
Brazil
Prior art keywords
treat
prevent
immunoglobulin molecule
processes
generate
Prior art date
Application number
BR9815580-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Ronald M Burch
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR9815580A publication Critical patent/BR9815580A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR9815580-6A 1997-11-14 1998-11-13 Composição de vacina, processos para gerar uma resposta de anti-idiótipo em um sujeito, para tratar ou prevenir câncer, para tratar ou prevenir uma doença infecciosa, para preparar uma primeira molécula de imunoglobulina, e, primeira molécula de imunoglobulina BR9815580A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6571697P 1997-11-14 1997-11-14
US8140398P 1998-04-10 1998-04-10
PCT/US1998/024303 WO1999025379A1 (en) 1997-11-14 1998-11-13 Modified antibodies with enhanced ability to elicit an anti-idiotype response

Publications (1)

Publication Number Publication Date
BR9815580A true BR9815580A (pt) 2002-01-29

Family

ID=26745908

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9815580-6A BR9815580A (pt) 1997-11-14 1998-11-13 Composição de vacina, processos para gerar uma resposta de anti-idiótipo em um sujeito, para tratar ou prevenir câncer, para tratar ou prevenir uma doença infecciosa, para preparar uma primeira molécula de imunoglobulina, e, primeira molécula de imunoglobulina
BR9815289-0A BR9815289A (pt) 1997-11-14 1998-11-13 Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9815289-0A BR9815289A (pt) 1997-11-14 1998-11-13 Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado

Country Status (9)

Country Link
EP (2) EP1032420A4 (ja)
JP (2) JP2001526021A (ja)
KR (2) KR20010015817A (ja)
CN (2) CN1294517A (ja)
AU (2) AU763029B2 (ja)
BR (2) BR9815580A (ja)
CA (2) CA2310269A1 (ja)
IL (2) IL136114A0 (ja)
WO (2) WO1999025378A1 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753753B2 (en) * 1998-11-13 2002-10-24 Euro-Celtique S.A. Contraceptive antibody vaccines
DK1092779T3 (da) * 1999-10-11 2010-02-15 Pasteur Institut Lentiviirusvektorer til fremstilling af immunterapeutiske præparater
AU2001261628A1 (en) * 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
DK1642910T3 (da) * 2000-12-05 2012-05-07 Alexion Pharma Inc Rationelt designede atistoffer
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
AU2002365926A1 (en) * 2001-10-25 2003-09-02 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
EP1938834B1 (en) * 2002-04-09 2012-04-25 The Curators Of The University Of Missouri Treatment of type 1 diabetes before and after expression of predisposition markers
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005021595A1 (en) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
AU2005219322B2 (en) * 2004-03-09 2008-09-18 Kyoto University Pharmaceutical Composition Comprising CXCR3 Inhibitor
ES2356830T3 (es) 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
CN101663321B (zh) * 2006-08-28 2014-10-08 协和发酵麒麟株式会社 拮抗型人light特异性人源性单克隆抗体
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
JP2011516041A (ja) * 2008-03-12 2011-05-26 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｔｙｒｐ１抗体
ES2495367T3 (es) * 2009-04-29 2014-09-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Anticuerpos monoclonales de ERG
CN102816240B (zh) * 2011-03-08 2014-02-12 中国人民解放军第三军医大学第二附属医院 一种融合蛋白及其融合蛋白表达载体
CA2837472A1 (en) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
LT2782598T (lt) * 2011-11-23 2020-07-27 In3Bio Ltd. Rekombinantiniai baltymai ir jų terapinis panaudojimas
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
CN105705522B (zh) * 2013-05-14 2020-09-15 上海亨臻实业有限公司 针对低免疫原性蛋白的表位疫苗及其制法和用途
CN103275914B (zh) * 2013-06-03 2015-04-01 中国人民解放军军事医学科学院微生物流行病研究所 展示保护性抗原的细菌菌蜕及其应用
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
WO2015177098A2 (en) * 2014-05-19 2015-11-26 Helsingin Yliopisto Modified adenoviruses for cancer vaccines development
CN105693859B (zh) * 2016-03-22 2019-06-21 苏州莱泰生物科技有限公司 抗人g2a单克隆抗体以及检测人巨噬细胞g2a表达量的试剂盒
CN111978382B (zh) * 2020-09-03 2022-03-04 吉林大学第一医院 一种球形孢子丝菌Gp70重组蛋白的制备方法及其应用
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
CA2047244C (en) * 1989-02-24 2002-09-17 Zanetti Maurizio Genetically engineered immunoglobulins
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
JPH09503901A (ja) * 1992-11-16 1997-04-22 キャンサー リサーチ ファンド オブ コントラ コスタ 広範な新生物特異性を有するペプチドおよびアンチセンスペプチド
WO1994014847A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
WO1994014848A1 (en) * 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia

Also Published As

Publication number Publication date
KR20010015818A (ko) 2001-02-26
AU763029B2 (en) 2003-07-10
AU1459899A (en) 1999-06-07
IL136114A0 (en) 2001-05-20
CA2309990A1 (en) 1999-05-27
AU1459799A (en) 1999-06-07
WO1999025379A1 (en) 1999-05-27
IL136113A0 (en) 2001-05-20
KR20010015817A (ko) 2001-02-26
WO1999025378A1 (en) 1999-05-27
JP2001526021A (ja) 2001-12-18
EP1030684A4 (en) 2004-09-15
AU737457B2 (en) 2001-08-23
JP2002507544A (ja) 2002-03-12
EP1030684A1 (en) 2000-08-30
BR9815289A (pt) 2001-12-26
WO1999025378A9 (en) 1999-08-12
EP1032420A4 (en) 2004-09-15
CN1327388A (zh) 2001-12-19
CN1294517A (zh) 2001-05-09
AU2003252902A1 (en) 2003-11-06
CA2310269A1 (en) 1999-05-27
EP1032420A1 (en) 2000-09-06

Similar Documents

Publication Publication Date Title
BR9815580A (pt) Composição de vacina, processos para gerar uma resposta de anti-idiótipo em um sujeito, para tratar ou prevenir câncer, para tratar ou prevenir uma doença infecciosa, para preparar uma primeira molécula de imunoglobulina, e, primeira molécula de imunoglobulina
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
BR9910023A (pt) Conjugados de poliol-ifn-beta
DE69429527T2 (de) Inhibitoren von beta-amyloid-protein-herstellung
DK1002064T3 (da) Modificeret polypeptid
BRPI9715334B8 (pt) agentes estrogênicos e composição farmacêutica compreendendo os mesmos.
EA199901063A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
BR9806925A (pt) Emulsão óleo-em-água, uso de uma emusão óleo-em-água, composição cosmética e/ou dermatológica, processo de tratamento cosmético e uso dos derivados de 1,3,5-triazina
NO20053920L (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
AR003457A1 (es) Una composicion tratante capilar antimicrobiana
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
BRPI0211200B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DE69230690D1 (de) Getreide-extrakte
IT1162895B (it) Solfonammidi derivate da 3 benziliden canfora e loro applicazione come filtri per raggi ultravioletti in particolare nelle composizioni cosmetiche
AR018535A1 (es) Conjugados de uno o mas fragmentos de anticuerpos covalentemente unido a una o mas moleculas de polimero no proteico, una composicion que los comprende y el uso de los mismos para la preparacion de un medicamento para tratar un trastorno inflamatorio en un mamifero.
BR9811099A (pt) Inibidores de urocinase
BRPI0516363A (pt) composição para cuidado dos cabelos e processo para preparação de uma composição
ES2135470T3 (es) Composiciones farmaceuticas y metodos que usan ibobutiramida para tratar trastornos de betaglobina.
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
PT965323E (pt) Agentes e suas composicoes para o tratamento do cabelo que contem sulfatos de fucano despolimerizados
ES549115A0 (es) Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores
ATE78397T1 (de) Verwendung von p-chlorophenoxyazetat von n,ndimethylbiguanidzur behandlung von neuropathien und nervendegeneration.
NO20010940L (no) TAN-1057 derivater

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.